Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st-Line Extensive Disease Small Cell Lung Cancer
This study has been completed.
Study NCT00320359 Information provided by GlaxoSmithKline
First Received: May 1, 2006 Last Updated: August 13, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Small Cell Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Small Cell
Lung Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Carcinoma, Neuroendocrine
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Intravenous etoposide/cisplatin
Intravenous topotecan/cisplatin
Additional drug interventions recognized in this trial
Cisplatin
Etoposide
Etoposide phosphate
Topotecan
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline
Back to top of Main Content
